In addition, low doses of synthetic drugs, such as the GSK-3 inhibitor IX (also known as BIO), an ATP-competitive inhibitor of GSK-3α/β, have found application in the pre-clinical evaluation of the beneficial effects of GSK-3 inhibition in the reduction of hepatic free fatty acid-depe...
Elraglusib (9-ING-41), an inhibitor of GSK-3, is a potent antitumor and immune-modulatory agent in phase 2 clinical trials for the treatment of various cancers. Here, we examined the immune environment of elraglusib-treated cancer patients by measuring peripheral blood protein levels to ...
AR-A014418 is an ATP-competitive, and selective GSK3β inhibitor with IC50 and Ki of 104 nM and 38 nM, without significant inhibition on 26 other kinases tested. 体外研究 体内研究 激酶实验 细胞实验 ~50 μM 动物实验 ~4mg/kg 腹腔注射 ...
cardiomyocytes and maintain self-renewal in both human and mouse embryonic stem cells through Wnt signaling activation. GSK-3 Inhibitor IX is also an inhibitor of Cdk5 and p35. Maintains self-renewal and pluripotency in embryonic stem cells via activation of the Wnt signaling pathway in vitro; ...
Inhibitor II was found to be a potent inhibitor of GSK-3β with the IC50 value of 390 nM. However, GSK-3β Inhibitor II was not able to inhibit another GSK-3 isoform, GSK-3α [1]. Another study found that GSK-3β Inhibitor II could block the functional regulation of p53 through ...
option in specific forms of cancer [96], [130], [131], GSK3 activity is reported to reduce the production of at least two tumour suppressors (Smad4 and PHLPP1 in Table 1) and there has been at least one GSK3 inhibitor taken to clinical trial for anti-tumourogenic potential (Table 2...
9-ING-41 is a small molecule potent selective GSK-3β inhibitor with antitumor activity. This study investigates 9-ING-41 in combination with carboplatin chemotherapy in patients with incurable, recurrent or metastatic salivary gland carcinomas (SGC). Patients with advanced SGC (including all histolo...
potentially suppressed by the brain-permeable PI3K/Akt inhibitor, paxalisib. The potent anti-DIPG/DMG pharmacokinetic and pharmacodynamic properties of ONC201 and paxalisib, coupled with the combined insights from these discoveries, are the basis for the ongoing DIPG/DMG phase II clinical trial, ...
AR-A014418(GSK3β Inhibitor VIII) 价 格 ￥800 起批量 ≥1支 最小起订1支 供货总量1000支 发货地址湖北省武汉市 建议售价￥100/支 更新日期 2025年04月25日 产品规格20mg 即时洽谈 立即询价 查看联系方式 收藏产品 发送留言 举报 VIP6年 武汉科斯坦生物科技有限公司 企业认证: 备 营业执照和...
Characterization of a GSK-3 inhibitor in culture of human cord blood primitive hematopoietic cells. Biomed Pharmacother. 2010;64:482–6. Article CAS PubMed Google Scholar Tolosa E, Litvan I, Hoglinger GU, Burn D, Lees A, Andres MV, et al. A phase 2 trial of the GSK-3 inhibitor ...